Theravance Biopharma (TBPH) Given a $55.00 Price Target by Cantor Fitzgerald Analysts

Share on StockTwits

Theravance Biopharma (NASDAQ:TBPH) received a $55.00 price objective from equities researchers at Cantor Fitzgerald in a report released on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 137.68% from the company’s previous close. Cantor Fitzgerald also issued estimates for Theravance Biopharma’s FY2019 earnings at ($3.74) EPS.

A number of other analysts also recently weighed in on the stock. BidaskClub downgraded shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 20th. Piper Jaffray Companies reissued an “overweight” rating and issued a $45.00 price target on shares of Theravance Biopharma in a report on Thursday, March 29th. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, March 28th. Leerink Swann increased their price target on shares of Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Finally, Zacks Investment Research downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. Four research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $39.29.

Shares of Theravance Biopharma traded up $0.12, hitting $23.14, during trading hours on Thursday, according to MarketBeat. 226,607 shares of the stock were exchanged, compared to its average volume of 240,350. The company has a current ratio of 4.25, a quick ratio of 4.08 and a debt-to-equity ratio of 3.53. The company has a market cap of $1.26 billion, a P/E ratio of -4.25 and a beta of 1.81. Theravance Biopharma has a one year low of $21.27 and a one year high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.26) by $0.04. Theravance Biopharma had a negative net margin of 1,383.47% and a negative return on equity of 188.96%. The business had revenue of $8.32 million during the quarter, compared to the consensus estimate of $5.74 million. equities research analysts forecast that Theravance Biopharma will post -4.8 EPS for the current fiscal year.

In other Theravance Biopharma news, CFO Renee D. Gala sold 10,000 shares of the stock in a transaction on Friday, May 18th. The shares were sold at an average price of $24.29, for a total value of $242,900.00. Following the completion of the sale, the chief financial officer now directly owns 236,022 shares of the company’s stock, valued at approximately $5,732,974.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.10% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. Woodford Investment Management Ltd raised its stake in shares of Theravance Biopharma by 0.4% in the 4th quarter. Woodford Investment Management Ltd now owns 10,747,108 shares of the biopharmaceutical company’s stock valued at $227,270,000 after buying an additional 41,000 shares in the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of Theravance Biopharma in the 4th quarter valued at $974,000. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma in the 4th quarter valued at $416,000. Schwab Charles Investment Management Inc. raised its stake in shares of Theravance Biopharma by 4.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock valued at $5,569,000 after buying an additional 8,119 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Theravance Biopharma by 15.7% in the 4th quarter. Wells Fargo & Company MN now owns 135,414 shares of the biopharmaceutical company’s stock valued at $3,777,000 after buying an additional 18,335 shares in the last quarter. Institutional investors own 85.94% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

DigitalNote Price Tops $0.0073
DigitalNote Price Tops $0.0073
Emercoin  Market Capitalization Tops $115.07 Million
Emercoin Market Capitalization Tops $115.07 Million
Blue Protocol Price Tops $0.14 on Exchanges
Blue Protocol Price Tops $0.14 on Exchanges
Grand Canyon Education  vs. OneSmart International Edun Gr  Critical Review
Grand Canyon Education vs. OneSmart International Edun Gr Critical Review
Telefonica  versus Koninklijke KPN  Financial Analysis
Telefonica versus Koninklijke KPN Financial Analysis
Investors Sell AbbVie  on Strength After Insider Selling
Investors Sell AbbVie on Strength After Insider Selling


© 2006-2018 Ticker Report. Google+.